Comparison of Optic Neuritis with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody and Seropositive Neuromyelitis Optica Antibody
10.3341/jkos.2021.62.4.538
- Author:
Min Chae KANG
1
;
Kyung-Ah PARK
Author Information
1. Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Publication Type:Original Article
- From:Journal of the Korean Ophthalmological Society
2021;62(4):538-544
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose:To compare clinical outcomes of Korean patients with seropositive myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-related optic neuritis (ON) and those with neuromyelitis optica antibody (NMO-IgG)-related ON.
Methods:Medical records were analyzed retrospectively among patients diagnosed with ON from January 2018 to June 2020, who were positive for MOG-IgG or NMO-IgG on serological tests. Clinical manifestations and outcomes were collected and compared between the two groups.
Results:The study included 14 eyes of 10 MOG-IgG positive patients, and 38 eyes of 25 NMO-IgG positive patients. Final visual acuity differed significantly between the two groups (p = 0.002), and the proportion of patients with no light perception was higher in the NMO-ON group (11%) compared with the MOG-ON group (0%). The mean deviation value on visual field tests also showed a significant difference between NMO-ON and MOG-ON groups (-18.98 ± 12.36 dB versus -10.17 ± 10.03 dB, respectively; p = 0.018). The recurrence rate was 42% in the NMO-ON group and 79% in the MOG-ON group (p = 0.020).
Conclusions:The clinical outcomes of NMO-ON and MOG-ON patients differed significantly. MOG-ON patients were more likely to experience a relapse. Patients with NMO-ON were given a poor visual prognosis despite having a lower recurrence rate than those with MOG-ON.
